2011
DOI: 10.1016/j.copbio.2010.08.010
|View full text |Cite
|
Sign up to set email alerts
|

Next generation microfluidic platforms for high-throughput protein biochemistry

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
17
0

Year Published

2011
2011
2023
2023

Publication Types

Select...
6
4

Relationship

0
10

Authors

Journals

citations
Cited by 26 publications
(17 citation statements)
references
References 37 publications
0
17
0
Order By: Relevance
“…MITOMI is a versatile platform capable of measuring a broad range of biomolecular interactions, including proteinprotein (27), protein-DNA (17,28), protein-RNA (29), and protein-small molecule (29). The integrated nature of the approach allows for the large-scale on-chip synthesis, purification, and characterization of proteins (30,31). A recent study by Bates and Quake showed that MITOMI could be adapted to enable the measurement of binding kinetics of a single antibody-antigen interaction (22).…”
mentioning
confidence: 99%
“…MITOMI is a versatile platform capable of measuring a broad range of biomolecular interactions, including proteinprotein (27), protein-DNA (17,28), protein-RNA (29), and protein-small molecule (29). The integrated nature of the approach allows for the large-scale on-chip synthesis, purification, and characterization of proteins (30,31). A recent study by Bates and Quake showed that MITOMI could be adapted to enable the measurement of binding kinetics of a single antibody-antigen interaction (22).…”
mentioning
confidence: 99%
“…Another field of application of mLSI is protein synthesis and characterization. In addition to high throughput, when married to DNA-to-protein arrays, mLSI has enabled multiplexed protein expression and utilization of advanced detection technologies, as summarized in the recent review by Maerkl on protein biochemistry [61].…”
Section: Biological and Chemical Applicationsmentioning
confidence: 99%
“…This transformation has been driven in part by development of new technologies for high-throughput data acquisition that now make it possible to sequence genomes (Metzker, 2009), and to measure RNA (Wang et al, 2009) and protein (Maerkl, 2011) expression levels with ever increasing accuracy and lower cost. These extraordinary achievements have contributed to advances in genetic medicine (Amberger et al, 2009) and the discovery of gene and protein signatures of disease (Wood et al, 2007; Hanash and Taguchi, 2010; Addona et al, 2011; Cancer Genome Atlas Research Network, 2011; Heidecker et al, 2011; Majewski and Bernards, 2011).…”
Section: Overviewmentioning
confidence: 99%